MarketCapExport financials
Atara Biotherapeutics (ATRA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Atara Biotherapeutics ATRA
$ 8.18
-0.12%
Facebook
X
Telegram
Atara Biotherapeutics Balance Sheet 2025-2011 | ATRA
Brief overview of Atara Biotherapeutics's financial position
Balance sheet changes are traced across five available annual reports between 2020 and 2024.
The asset base decreased -81.4%, from $588.1 million to $109.1 million. Resources became smaller over the five periods.
Funding shifted toward liabilities: they gained +64.1%, compared with -81.4% for assets.
The period ended with negative equity, a structure associated with elevated financial vulnerability.
Cash equals 22.9% of the balance sheet, compared with 34.3% five periods ago. This is the readily available cushion.
Retained earnings are negative at -$2.1 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Balance sheet takeaway
Taken together, Atara Biotherapeutics's balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.
Annual Balance Sheet Atara Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
1.89 M | 17.8 M | 31.1 M | -22.1 M | -103 M | -199 M | -58.6 M | -60.7 M | -79.2 M | -48 M | -23.7 M | -21.9 M | -51.6 M | -4.21 M | - |
Long Term Debt |
9.35 M | 29.9 M | 45.7 M | 58.1 M | 29 K | 149 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.03 M | 12.9 M | 11.3 M | 12.8 M | 2.58 M | 1.73 M | 1.31 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
43.8 M | 71.8 M | 123 M | 171 M | 82.7 M | 42.9 M | 15.4 M | 13 M | 12.3 M | 503 K | 166 K | 216 K | 61.3 M | 6.72 M | - |
Total Current Liabilities |
14.9 M | 135 M | 142 M | 78.9 M | 106 M | 82.9 M | 36.7 M | 40 M | 27.6 M | 9.68 M | 9.71 M | 2.72 M | - | - | - |
Total Liabilities |
58.7 M | 206 M | 265 M | 250 M | 189 M | 126 M | 52.2 M | 53 M | 39.9 M | 10.2 M | 9.88 M | 2.94 M | 62.8 M | 8.02 M | - |
Deferred Revenue |
- | - | 77.8 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.02 B | -2.05 B | -1.97 B | -1.69 B | -1.46 B | -1.12 B | -818 M | -527 M | -297 M | -177 M | -98.1 M | -40.9 M | -12.9 M | -4.11 M | - |
Total Assets |
20.2 M | 109 M | 166 M | 376 M | 468 M | 588 M | 343 M | 392 M | 218 M | 264 M | 325 M | 106 M | 51.8 M | 4.29 M | - |
Cash and Cash Equivalents |
8.48 M | 25 M | 25.8 M | 92.9 M | 106 M | 200 M | 74.3 M | 60.7 M | 79.2 M | 48 M | 23.7 M | 21.9 M | 51.6 M | 4.21 M | - |
Book Value |
-38.5 M | -97.3 M | -99.2 M | 127 M | 280 M | 462 M | 291 M | 339 M | 178 M | 254 M | 315 M | 103 M | -11 M | -3.73 M | - |
Total Shareholders Equity |
-38.5 M | -97.3 M | 99.2 M | 127 M | 280 M | 462 M | 291 M | 339 M | 178 M | 254 M | 315 M | 103 M | -11 M | -3.73 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Atara Biotherapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
8.48 M | 8.78 M | 9.08 M | 9.35 M | 15 M | 15.4 M | 26.7 M | 29.9 M | 35.2 M | 38.7 M | 42.2 M | 45.7 M | 48.5 M | 51.8 M | 54.9 M | 58.1 M | 61.1 M | 64 M | 17.5 M | 25.5 M | 24.6 M | 12.2 M | 12.6 M | 13 M | 13.1 M | 13.4 M | 13.8 M | 14.1 M | 14.5 M | 14.9 M | 14.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
49.9 M | 51.2 M | 51.7 M | 43.8 M | 48.7 M | 57.4 M | 69.2 M | 71.8 M | 77.3 M | 79.9 M | 82.9 M | 123 M | 161 M | 164 M | 169 M | 171 M | 109 M | 113 M | 71.4 M | 82.7 M | 53.6 M | 36.4 M | 46.4 M | 42.9 M | 15.5 M | 15.3 M | 15.2 M | 15.4 M | 15.6 M | 16.1 M | 15.6 M | 13 M | 12.9 M | 13 M | 12.9 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 503 K | 503 K | 503 K | 503 K | 166 K | 166 K | 166 K | 166 K | 216 K | 165 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
56.5 M | 58 M | 57.3 M | 58.7 M | 66.8 M | 71.9 M | 117 M | 206 M | 233 M | 228 M | 264 M | 265 M | 240 M | 239 M | 237 M | 250 M | 181 M | 179 M | 173 M | 189 M | 140 M | 125 M | 131 M | 126 M | 51.6 M | 47 M | 46.7 M | 52.2 M | 46.3 M | 41.9 M | 40.8 M | 53 M | 53 M | 53 M | 53 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 9.88 M | 9.88 M | 9.88 M | 9.88 M | 2.94 M | 2.58 M | 2.94 M | 2.94 M | 1.75 M | 1.75 M | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
513 K | - | - | 716 K | - | - | - | - | - | - | - | 77.8 M | - | - | - | - | - | - | - | - | 31.2 M | 41 M | 35.5 M | 33.5 M | - | 33.5 M | 33.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.03 B | -2.03 B | -2.03 B | -2.02 B | -2.02 B | -2.01 B | -2.02 B | -2.05 B | -2.04 B | -2.02 B | -2 B | -1.97 B | -1.91 B | -1.84 B | -1.77 B | -1.69 B | -1.62 B | -1.53 B | -1.55 B | -1.46 B | -1.37 B | -1.29 B | -1.2 B | -1.12 B | -1.04 B | -969 M | -891 M | -818 M | -739 M | -668 M | -593 M | -527 M | -527 M | -527 M | -527 M | -297 M | -297 M | -297 M | -297 M | -177 M | -177 M | -177 M | -177 M | -98.1 M | -98.1 M | -98.1 M | -98.1 M | -40.9 M | -30.4 M | -40.9 M | -40.9 M | -12.9 M | -12.9 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
18.6 M | 21 M | 20 M | 20.2 M | 30.2 M | 36.9 M | 62 M | 109 M | 143 M | 117 M | 165 M | 166 M | 189 M | 246 M | 302 M | 376 M | 368 M | 436 M | 397 M | 468 M | 450 M | 457 M | 530 M | 588 M | 406 M | 428 M | 300 M | 343 M | 365 M | 274 M | 325 M | 392 M | 392 M | 392 M | 392 M | 218 M | 218 M | 218 M | 218 M | 264 M | 264 M | 264 M | 264 M | 325 M | 325 M | 325 M | 325 M | 106 M | 54.1 M | 106 M | 106 M | 51.8 M | 51.8 M | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
4.06 M | 3.22 M | 8.36 M | 8.48 M | 5.74 M | 16.9 M | 14 M | 25.2 M | 46.6 M | 31.5 M | 35.2 M | 26 M | 64.9 M | 46 M | 48.9 M | 93.1 M | 66.5 M | 72 M | 103 M | 107 M | 115 M | 125 M | 152 M | 202 M | 64 M | 75.9 M | 71.6 M | 75.7 M | 95.8 M | 60.6 M | 57.6 M | 62.1 M | 60.7 M | 60.7 M | 60.7 M | 80.6 M | 79.2 M | 79.2 M | 79.2 M | 48.2 M | 48 M | 48 M | 48 M | 23.9 M | 23.7 M | 23.7 M | 23.7 M | 21.9 M | 25.7 M | 21.9 M | 21.9 M | 51.6 M | 51.6 M | - | - | 4.21 M | - | - | - | - | - | - | - |
Book Value |
-37.9 M | -37 M | -37.3 M | -38.5 M | -36.6 M | -35 M | -55.1 M | -97.3 M | -90.5 M | -111 M | -98.3 M | -99.2 M | -50.8 M | 7.45 M | 65 M | 127 M | 187 M | 257 M | 224 M | 280 M | 310 M | 332 M | 399 M | 462 M | 354 M | 381 M | 253 M | 291 M | 318 M | 232 M | 284 M | 339 M | 339 M | 339 M | 339 M | 178 M | 178 M | 178 M | 178 M | 254 M | 254 M | 254 M | 254 M | 315 M | 315 M | 315 M | 315 M | 103 M | 51.5 M | 103 M | 103 M | 50.1 M | 50.1 M | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-37.9 M | -37 M | -37.3 M | -38.5 M | -36.6 M | -35 M | -55.1 M | -97.3 M | -90.5 M | -111 M | -98.3 M | 99.2 M | -50.8 M | 7.45 M | 65 M | 127 M | 187 M | 257 M | 224 M | 280 M | 310 M | 332 M | 399 M | 462 M | 354 M | 381 M | 253 M | 291 M | 318 M | 232 M | 284 M | 339 M | 339 M | 339 M | 339 M | 178 M | 178 M | 178 M | 178 M | 254 M | 254 M | 254 M | 254 M | 315 M | 315 M | 315 M | 315 M | 103 M | -23 M | 103 M | 103 M | -11 M | -11 M | - | - | -3.73 M | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Atara Biotherapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Exelixis
EXEL
|
$ 71.0 | -1.04 % | $ 19.3 B |  USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | USA |
 |
Amgen
AMGN
|
$ 465.26 | 0.01 % | $ 250 B | USA |
 |
Biogen
BIIB
|
$ 253.37 | -0.59 % | $ 37.1 B | USA |
 |
Edesa Biotech
EDSA
|
$ 2.01 | -19.28 % | $ 11.4 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 15.12 | -0.72 % | $ 978 M | USA |
 |
Achieve Life Sciences
ACHV
|
$ 6.78 | 0.89 % | $ 296 M | USA |
 |
Fulcrum Therapeutics
FULC
|
$ 3.72 | -0.13 % | $ 236 M | USA |
 |
Immutep Limited
IMMP
|
$ 3.53 | -7.11 % | $ 5.14 B |  Australia |
 |
Iovance Biotherapeutics
IOVA
|
$ 8.09 | -1.04 % | $ 2.89 M | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.37 | 28.7 % | $ 2.91 M |  Israel |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.71 | -2.5 % | $ 134 M | USA |
 |
Axsome Therapeutics
AXSM
|
$ 141.12 | 5.34 % | $ 7.02 B | USA |
 |
Keros Therapeutics
KROS
|
$ 9.32 | 1.64 % | $ 347 M | USA |
 |
Champions Oncology
CSBR
|
$ 4.85 | 0.21 % | $ 67.1 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 10.6 | -2.12 % | $ 303 M | USA |
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | USA |
 |
Immunic
IMUX
|
$ 8.06 | 1.26 % | $ 1.25 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 9.7 | 0.47 % | $ 456 M | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.74 | 0.63 % | $ 5.94 B |  Spain |
 |
Incyte Corporation
INCY
|
$ 120.28 | -1.32 % | $ 23.5 B | USA |
 |
AC Immune SA
ACIU
|
$ 2.32 | -4.92 % | $ 234 M |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.64 | 0.53 % | $ 38.4 M | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M |  Canada |
 |
Precision BioSciences
DTIL
|
$ 9.47 | -2.17 % | $ 121 M | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.14 | -11.15 % | $ 227 K | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 256.21 | -1.4 % | $ 15.5 B |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
$ 71.31 | 5.19 % | $ 1.43 B | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.56 | 1.3 % | $ 48.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.31 | -0.76 % | $ 349 M |  Britain |
|
Monopar Therapeutics
MNPR
|
$ 71.42 | -3.16 % | $ 529 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 78.67 | 0.95 % | $ 15.1 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 7.53 | -1.38 % | $ 1.58 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.68 | -2.39 % | $ 255 M | Britain |
 |
Coherus BioSciences
CHRS
|
$ 0.64 | -21.66 % | $ 75 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 27.45 | 4.77 % | $ 3.49 B | USA |
 |
Cellectis S.A.
CLLS
|
$ 1.12 | -0.45 % | $ 112 M |  France |
 |
BeyondSpring
BYSI
|
$ 0.6 | -2.21 % | $ 24.7 M | USA |
 |
Alkermes plc
ALKS
|
$ 46.48 | 0.67 % | $ 7.66 B |  Irlanda |
 |
Altimmune
ALT
|
$ 1.94 | -8.51 % | $ 171 M | USA |
 |
Cardiff Oncology
CRDF
|
$ 0.79 | -0.77 % | $ 52.8 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.5 | -5.43 % | $ 5.53 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 9.41 | -0.84 % | $ 258 M | Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 49.04 | -0.41 % | $ 6.56 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | -1.93 % | $ 2.19 B | Canada |
 |
Cullinan Management
CGEM
|
$ 11.34 | -3.32 % | $ 683 M | USA |
 |
BioNTech SE
BNTX
|
$ 87.2 | -0.36 % | $ 21.1 B |  Germany |
 |
Collegium Pharmaceutical
COLL
|
$ 24.47 | -0.97 % | $ 775 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 3.95 | 12.07 % | $ 52.6 M | USA |